Get the Stockscreener App
87.91
4.07%
3.44
After Hours:
87.87
-0.04
-0.05%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $87.91, with a volume of 12.30M.
It is up +4.07% in the last 24 hours and down -9.19% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$84.47
Open:
$84.86
24h Volume:
12.30M
Relative Volume:
1.04
Market Cap:
$153.12B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
24.49
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
+6.48%
1M Performance:
-9.19%
6M Performance:
-32.38%
1Y Performance:
-34.78%
1-Day Range:
$84.40
$87.92
1-Week Range:
$82.69
$87.92
52-Week Range:
$81.97
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
87.91 | 147.13B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
313.22 | 117.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.32 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.92 | 78.30B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.39 | 46.86B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
A Look at Abbott Laboratories (ABT) After 4.1% Gain -- GF Value $127.69 vs Price $87.91 - GuruFocus
Abbott Laboratories Stock (ABT) Moved Up by 3.04% on May 18: What Investors Need To Know - TradingKey
Boston Scientific Bets on Growth Through Strategic M&A Deals - TradingView
Raised full-year 2026 outlook lifts Abbott stock 3.18% - Traders Union
Trump’s stock trading spree included North Chicago’s Abbott Labs - Crain's Chicago Business
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now? - TradingView
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Thrivent Financial for Lutherans Acquires 48,286 Shares of Abbott Laboratories $ABT - MarketBeat
North Dakota State Investment Board Purchases New Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Purchased by Cambridge Investment Research Advisors Inc. - MarketBeat
Abbott Laboratories stock (US0028241000): Q1 2026 growth, guidance raise and diabetes momentum - AD HOC NEWS
Abbott Laboratories stock (US0028241000): diabetes growth and fresh guidance keep investors focused - AD HOC NEWS
Abbott Laboratories Stock (ABT) Opinions on Recent Price Declines - Quiver Quantitative
Abbott Laboratories stock (US0028241000): diabetes segment drives attention after latest quarterly u - AD HOC NEWS
Abbott Laboratories $ABT Stock Holdings Lowered by iA Global Asset Management Inc. - MarketBeat
AlphaCore Capital LLC Increases Stock Position in Abbott Laboratories $ABT - MarketBeat
Abacus Wealth Partners LLC Buys 12,260 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Trade Ideas — LSX:850103 - TradingView
Assessing Abbott Laboratories (ABT) Valuation After Nutrition Setbacks Legal Uncertainty And Softer Analyst Sentiment - simplywall.st
Commerzbank Aktiengesellschaft FI Sells 131,572 Shares of Abbott Laboratories $ABT - MarketBeat
Bessemer Group Inc. Sells 213,665 Shares of Abbott Laboratories $ABT - MarketBeat
ABT (NYSE: ABT) Form 144 shows 7,587 RSU shares and prior 29,211 sale - Stock Titan
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Is Abbott’s Exact Sciences Deal And Nutrition Pivot Altering The Investment Case For Abbott (ABT)? - Yahoo Finance
Better medical device stock right now: Abbott Laboratories vs. Dexcom - MSN
Abbott Laboratories slammed on its post-Exact Sciences guidance - MSN
Is the options market predicting a spike in Abbott Laboratories stock? - MSN
Abbott Laboratories stock (US0028241000): Q1 beat, Exact Sciences deal and legal risks keep investor - AD HOC NEWS
Abbott class action alleges FreeStyle Libre 2 glucose monitor is defective - Class Action Lawsuits
How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up - Yahoo Finance
Phoenix Financial Ltd. Increases Stock Position in Abbott Laboratories $ABT - MarketBeat
Summit Wealth Group LLC Co. Sells 21,449 Shares of Abbott Laboratories $ABT - MarketBeat
Conning Inc. Grows Position in Abbott Laboratories $ABT - MarketBeat
Top Abbott Laboratories (ABT) Competitors 2026 - MarketBeat
Exact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT) - simplywall.st
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
ABT Stock Quote Price and Forecast - CNN
Exact Sciences Corp. stock (US30063P1057): Acquired by Abbott for $20.6B - AD HOC NEWS
Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment - Insider Monkey
Abbott Laboratories stock (US0028241000): shares rebound after earnings and guidance update - AD HOC NEWS
Insider trades: Okta and Abbott see buys, Micron insiders sell - MSN
What to know about Kyle Diamantas, the new acting FDA commissioner - The Guardian
How The Investment Narrative For Abbott Laboratories (ABT) Is Shifting With Recent Analyst Resets - Yahoo Finance
Nvision secures $55 million, with backing from Abbott - BioWorld News
Abbott Eterna Lawsuit Alleges Spinal Cord Stimulator Malfunction Resulted in Worsening Pain - AboutLawsuits.com
Abbott Laboratories Deadline Alert - TMX Newsfile
Abbott Laboratories stock (US0028241000): Q4 earnings call set for Jan. 22 - AD HOC NEWS
Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold? - Yahoo Finance
Abbott Securities Lawsuit Deepens Infant Formula Risks For Shareholders - simplywall.st
Abbott India Limited Issues Postal Ballot Notice for Appointment of Mr. James Wenner and Mr. Neeraj Jain to Its Board - scanx.trade
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abbott Laboratories Stock (ABT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STARKS DANIEL J | Director |
Apr 27 '26 |
Buy |
92.65 |
10,000 |
926,537 |
6,751,103 |
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):